CytoSorbents, Inc. Continues to Expand Market Awareness of Its Technologies

MONMOUTH JUNCTION, NJ--(Marketwire - September 27, 2012) - CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to modulate the immune response, control inflammation, and prevent or treat organ failure, continues to expand market awareness of its CytoSorb® and HemoDefend technologies through exhibits, posters and presentations at a number of key conferences through the end of 2012. These include:

• HAI 2012 (Congress for Anesthesiology and Intensive Care Therapy) - Berlin, Germany - September 13-15, 2012
• ESAO 2012 (European Society for Artificial Organs) - Rostock, Germany - September 26-29, 2012
• AABB & CTTXPO 2012 (American Association of Blood Banks) - Boston, MA - October 6-9, 2012
• ESICM 2012 (European Society of Intensive Care Medicine) - Lisbon, Portugal - October 13-17, 2012
• Brean Murray Caret Life Sciences Summit - New York City, NY - November 7, 2012
• DIVI 2012 (German Interdisciplinary Association for Intensive Care and Emergency Medicine) - Hamburg, Germany - December 5-7, 2012

At ESAO 2012, Dr. Kai Singbartl, MD, MPH will present pre-clinical and clinical data on CytoSorb® in his talk “Cytokine Adsorption in Sepsis” during a symposium on the “Extracorporeal Treatment of Sepsis” chaired by Dr. Patrick Honoré and Dr. Steffen Mitzner. At the University of Pittsburgh, Dr. Singbartl collaborated with Dr. John Kellum on seminal work relating to the effect of CytoSorb® on leukocyte trafficking, inflammation, and organ injury in animal models of sepsis.

At AABB 2012, CytoSorbents was selected for a poster presentation on its HemoDefend technology based upon its abstract “In situ removal of antibodies, free hemoglobin, cytokines and bioactive lipids from pRBCs using hemoadsorbent polymer beads.” CytoSorbents will also exhibit its unique “Beads in a Bag” and in-line filter technology for the removal of contaminants that can cause transfusion reactions in transfused blood products.

At the Brean Murray Life Sciences Summit, the company will be among one of more than 30 select public companies to make in-depth group and one-on-one presentations to key institutional investors in the medical device, biotechnology and pharmaceutical sectors.

In addition to this schedule, CytoSorbents will also attend and exhibit at several local and regional conferences in Germany focused on intensive care medicine and extracorporeal therapies.

About Dr. Kai Singbartl

Dr. Kai Singbartl, MD, MPH is Associate Professor of Anesthesiology at Milton S. Hershey Medical Center at Penn State Hershey. Previously, he was Associate Professor of Critical Care Medicine at University of Pittsburgh. Dr. Singbartl’s research has focused on the effect of inflammation on organ injury, in particular leukocyte trafficking and acute kidney injury in sepsis. He has also co-developed new urinary biomarkers to predict long-term dialysis dependency. His past research interests include the effects of cryopreservation on red blood cells. His research efforts have been published in leading clinical and scientific journals and he has received a number of awards for his research from international societies. Dr. Singbartl has also presented talks at various national and international meetings, including the Society of Critical Care Medicine (SCCM), the European Society of Intensive Care Medicine (ESICM), American Thoracic Society (ATS), Experimental Biology, and the International Symposium on Intensive Care and Emergency Medicine (ISICEM). He has also been invited to give plenary lectures and chair sessions at leading international meetings, including CHEST and ISICEM.

About CytoSorbents, CytoSorb®, and HemoDefend

CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. In 2011, CytoSorb®, the Company’s flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, allowing it to be sold throughout the European Union (E.U.) under the CE Mark, to be used in clinical situations where cytokines are elevated. The goal of CytoSorb® is to modulate the immune system by reducing “cytokine storm” in critically-ill patients that could otherwise lead to deadly inflammation, multiple organ failure, immune dysfunction, and often death in common illnesses such as sepsis, trauma, burn injury, acute respiratory distress syndrome, and pancreatitis. CytoSorb® has demonstrated statistically significant reductions in mortality in septic patients at high risk of death in early studies and is now being sold in Germany, Austria and Switzerland for the treatment of critical care illnesses, with availability in other E.U. countries planned in the future, assuming adequate and timely funding, and continued positive results from clinical studies.

HemoDefend is a development-stage blood purification technology platform for the blood transfusion industry intended to reduce transfusion reactions and safeguard the quality and safety of the blood supply. The HemoDefend technology utilizes the Company’s polymer bead technology to remove many substances, such as antibodies, free hemoglobin and inflammatory mediators that can cause potentially serious and sometimes fatal transfusion reactions.

CytoSorb® and HemoDefend are just two of a number of different polymers the Company has designed for various medical applications, including improved dialysis, reduction of post-surgical complications in cardiac surgery, treatment of inflammatory and autoimmune disorders, radio-imaging contrast removal in imaging and interventional radiology procedures, and the treatment of rhabdomyolysis, drug overdose, and others. Additional information is available for download on the Company’s website: www.cytosorbents.com

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management’s current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and additional CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company’s medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate and timely financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company’s products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company’s Form 10-K filed with the SEC on March 30, 2012, which is available at http://www.sec.gov.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1985309